BMO Capital Markets. "As the industry evolves, our priority is providing exceptional service to our clients while delivering more integrated and innovative solutions to grow our market leading ...

BMO Capital Markets. "As the industry evolves, our priority is providing exceptional service to our clients while delivering more integrated and innovative solutions to grow our market leading ...

Alimentation Couche-Tard (TSE:ATD – Get Free Report) had its target price dropped by investment analysts at BMO Capital Markets from C$87.00 to C$85.00 in a research report issued on Monday ...

GrafTech International (NYSE:EAF – Get Free Report) had its price objective cut by stock analysts at BMO Capital Markets from $2.00 to $1.50 in a report issued on Monday,Benzinga reports.

On Tuesday, BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears ...

Investing.com -- Analysts at JP Morgan and BMO Capital Markets downgraded Air Products and Chemicals Inc (NYSE:APD) on concerns over earnings growth, currency headwinds, and management transition.

Tuesday, BMO Capital Markets highlighted the potential risks faced by Real Estate Investment Trusts (REITs) specializing in Skilled Nursing Facilities (SNFs) due to possible changes in Federal ...

BMO Capital raised the firm’s price target on HubSpot (HUBS) to $885 from $690 and keeps an Outperform rating on the shares. The company ...

BMO Capital analyst Brian Pitz lowered the firm’s price target on Trade Desk (TTD) to $115 from $160 after its Q4 results and below consensus ...

Tuesday, BMO Capital Markets highlighted the potential risks faced by Real Estate Investment Trusts (REITs) specializing in Skilled Nursing Facilities (SNFs) due to possible changes in Federal Medical ...

BMO Capital Markets updated its outlook on Expedia Group Inc. (NASDAQ:EXPE), raising the price target from $165.00 to $190.00 ...

On Tuesday, BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears ...